AbbVie (NYSE:ABBV) Stock Price Expected to Rise, Morgan Stanley Analyst Says

AbbVie (NYSE:ABBV) had its target price raised by research analysts at Morgan Stanley from $310.00 to $346.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley‘s price target suggests a potential upside of 19.83% from the stock’s current price.

ABBV has been the subject of a number of other reports. Cantor Fitzgerald raised their price objective on AbbVie from $290.00 to $325.00 and gave the company an “overweight” rating in a research report on Monday. Guggenheim raised their price target on AbbVie from $288.00 to $322.00 and gave the company a “buy” rating in a report on Monday. BMO Capital Markets lifted their price objective on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Finally, JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $291.04.

AbbVie Price Performance

NYSE ABBV traded down $6.15 on Monday, hitting $288.74. 3,468,088 shares of the stock were exchanged, compared to its average volume of 6,314,788. The company has a market capitalization of $510.15 billion, a PE ratio of 49.65, a P/E/G ratio of 1.35 and a beta of 0.24. The business’s fifty day moving average is $269.35 and its 200 day moving average is $237.23. AbbVie has a 52 week low of $190.75 and a 52 week high of $298.74.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same period in the previous year, the business earned $1.86 EPS. AbbVie’s revenue for the quarter was up 10.3% compared to the same quarter last year. Analysts predict that AbbVie will post 13.92 EPS for the current fiscal year.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Several institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LP bought a new stake in shares of AbbVie during the 2nd quarter worth $559,736,000. Legal & General Group Plc bought a new position in AbbVie in the second quarter valued at about $2,905,952,000. Jupiter Topco LLC acquired a new position in AbbVie during the second quarter worth about $1,560,354,000. Canada Pension Plan Investment Board bought a new position in shares of AbbVie in the second quarter worth about $817,473,000. Finally, The Manufacturers Life Insurance Company bought a new position in AbbVie in the 2nd quarter valued at approximately $655,268,000. 70.23% of the stock is currently owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie beat third-quarter earnings and revenue expectations, while management raised its 2026 revenue and adjusted earnings outlook. Growth from immunology drugs Skyrizi and Rinvoq, along with neuroscience products, is driving momentum as the company moves beyond Humira’s decline. ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
• Positive Sentiment: Several analysts raised their price targets following the results. Targets include $330 from RBC, $325 from Cantor Fitzgerald, and as high as $338 from Canaccord Genuity, with bullish ratings maintained or initiated. These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results
• Positive Sentiment: AbbVie increased its quarterly dividend 5.2% to $1.82 per share, or $7.28 annualized, supporting the stock’s appeal to income-focused investors. AbbVie Stock Hits a Record After a 5.2% Dividend Raise
• Neutral Sentiment: A Phase 2 study found experimental ABBV-466 nearly doubled Skyrizi’s Crohn’s disease remission rate, offering potential for another blockbuster product, although the treatment remains investigational and clinical and regulatory risks remain. Prediction: AbbVie’s Next Blockbuster Is Hiding in a Two-Drug Crohn’s Combo
• Negative Sentiment: Valuation is a potential headwind: AbbVie trades at a comparatively high earnings multiple after a substantial rally, while some investors may prefer lower-valued peers such as Bristol Myers Squibb. Continued execution is needed to justify the premium and offset legacy-product declines. AbbVie vs. Bristol Myers Squibb

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.